| Literature DB >> 33557287 |
Eun Ji Roh1,2, Anjani Darai1,2, Jae Won Kyung1, Hyemin Choi1, Su Yeon Kwon1, Basanta Bhujel1,2, Kyoung Tae Kim3,4, Inbo Han1.
Abstract
Intervertebral disc (IVD) degeneration can cause chronic lower back pain (LBP), leading to disability. Despite significant advances in the treatment of discogenic LBP, the limitations of current treatments have sparked interest in biological approaches, including growth factor and stem cell injection, as new treatment options for patients with chronic LBP due to IVD degeneration (IVDD). Gene therapy represents exciting new possibilities for IVDD treatment, but treatment is still in its infancy. Literature searches were conducted using PubMed and Google Scholar to provide an overview of the principles and current state of gene therapy for IVDD. Gene transfer to degenerated disc cells in vitro and in animal models is reviewed. In addition, this review describes the use of gene silencing by RNA interference (RNAi) and gene editing by the clustered regularly interspaced short palindromic repeats (CRISPR) system, as well as the mammalian target of rapamycin (mTOR) signaling in vitro and in animal models. Significant technological advances in recent years have opened the door to a new generation of intradiscal gene therapy for the treatment of chronic discogenic LBP.Entities:
Keywords: CRISPR-Cas9; RNAi; genetic therapy; intervertebral disc degeneration; mTOR signaling; vector
Mesh:
Year: 2021 PMID: 33557287 PMCID: PMC7914740 DOI: 10.3390/ijms22041579
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923